Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

Eli Lilly (LLY) ended the recent trading session at $1,229.93, demonstrating a +1.81% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 1.18%. Elsewhere, the Dow saw an upswing of 0.59%, while the tech-heavy Nasdaq appreciated by 2.07%. Heading into today, shares of the drugmaker had gained 9.33% over the past month, outpacing the Medical sector's gain of 7.96% and the S&P 500's loss of 2.9%.The upcoming earnings release of Eli Lilly will be of great interest to investors. The company is expected to report EPS of $9.01, up 42.79% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $20.44 billion, showing a 31.39% escalation compared to the year-ago quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $35.67 per share and revenue of $85.6 billion. These totals would mark changes of +47.34% and +31.33%, respectively, from last year. Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.02% higher. As of now, Eli Lilly holds a Zacks Rank of #3 (Hold). In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 33.87. This denotes a premium relative to the industry average Forward P/E of 15.73. Investors should also note that LLY has a PEG ratio of 1.33 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.74 as of yesterday's close. The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 38% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.See Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks